Background and aim: Genistein is an isoflavone that acts as a potent inhibitor of tyrosine kinase in several cancers. The aim of this study was to elucidate the impact of genistein on leukemia cell lines through E-cadherin signaling pathway. 
Methods: This study was conducted in 2016 at the Molecular Medicine Research Center (Hormozgan University of Medical Sciences, Bandar Abbas, Iran). In this in vitro experimental study, the Acute leukemia lymphoma (ALL) cell lines MOLT4 (as mild acute lymphoblastic leukemia cell line) and JURKAT (as high aggressive acute lymphoblastic leukemia cell line) were cultured and then treated with different concentrations of genistein (10, 25, 40 and 55 μM) for 24, 48 and 72 hours. Its cytotoxicity and anti-cancer properties on ALL cell lines were evaluated by calculating the growth rate and MTT assay. Eventually, the effect of genistein on the expression level of E-cadherin was examined using a quantitative Real-Time PCR. In the present research, we used in vitro experimental study. 
Results: The percentage of vital malignant cells treated with genistein in comparison with non-treated cells was significantly decreased (p<0.03). E-cadherin expression was significantly (p<0.02) up-regulated between 2 to 4 times as compared with non-treated ones. Even though it seems that genistein induces its anti-cancer properties on all doses, it was found that there is a negative correlation between these anti-cancer properties and increasing the concentration and exposure time of genistein. 
Conclusion: The present findings suggest that genistein possesses a growth inhibitory effect on ALL similar to solid tumor cells. It can also be deduced that genistein could be considered as a natural agent to potentially control the invasion of malignant cells and expedition of disease, which is promising and fascinating. From increasing the expression of E-cadherin as a tumor suppressor gene, what it is pioneering in reporting is another mechanism of action of genistein.
Keywords: Cell lymphoblastic leukemia-lymphoma; Cadherins; Genistein


» HTML Fulltext    » PDF Fulltext    » doi: 10.19082/7391
sneakersAir Jordan 1 Retro High OG "Obsidian" Sail/Obsidian-University Blue For Sale

The  most recent editorial (June 2021)

Ethics of Publishing Case Reports: Do We Need Ethics Approval and Patient Consent?

An editorial by Dr. Mehrdad Jalalian

Read more.

The worldwide spread of COVID-19 as an emerging, rapidly evolving situation, and the dramatic need of urgent medicine or vaccine, has rapidly brought new hypotheses for pathophysiology and potential medicinal agents to the fore. It is crucial that the research community provide a way to publish this research in a timely manner.


To contribute to this important public health discussion, the Electronic Physician Journal is excited to announce a fast-track procedure to help researchers publish their articles on COVID-19 related subjects that fall under the broad definition of public health, internal medicine, and pharmacology. We are especially welcome to all hypotheses about the pathological basis of the COVID-19 infection and the possible characteristics of potential medicine and vaccine. Submit your manuscript here


Our previous editorial (June 2020)

Lessons from COVID-19 pandemic and the Morocco’s success story.

An editorial by Dr. Benksim Abdelhafid (Morocco)

Read more.


The 6th World Conference on Research Integrity (WCRI) is to be held on June 2-5, 2019 in Hong Kong.

The WCRI is the largest and most significant international conference on research integrity. Since the first conference in Lisbon in 2007, it has given researchers, teachers, funding agencies, government officials, journal editors, senior administrators, and research students opportunities to share experiences and to discuss and promote integrity in research. Read more:


TDR Clinical Research and Development Fellowships

Call for applications

Deadline for submission: 7 March 2019, 16:00 (GMT)

TDR provides fellowships for early- to mid-career researchers and clinical trial staff (e.g. clinicians, pharmacists, medical statisticians, data managers, other health researchers) in low- and middle-income countries (LMICs) to learn how to conduct clinical trials. Read more:

Meta-Analysis Workshops in New York, USA, and London, UK, in April and May 2019

Don't miss this exceptional opportunity to learn how to perform and report a Meta-analysis correctly. Two Meta-analysis workshops are organized in April and May 2019 by Dr. Michael Borenstein in New York, USA (April 08-10, 2019) and London, UK (May 27-29).

About the Instructor

Dr. Michael Borenstein, one of the authors of Introduction to Meta-Analysis, is widely recognized for his ability to make statistical concepts accessible to researchers as well as to statisticians. He has lectured widely on meta-analysis, including at the NIH, CDC, and FDA. Read more: